Decrease in Alpha-fetoprotein from >1000 to <500 ng/mL in Waitlisted Patients with Hepatocellular Carcinoma Resulted in Improved Post-Transplant Survival and Reduced Risk of Tumor Recurrence: Validation of the Current National Policy
AASLD LiverLearning®, Francis Yao, 201324
A risk prediction score based on magnetic resonance cholangiopancreatography (MRCP) accurately predicts disease progression in patients with primary sclerosing cholangitis (PSC)
AASLD LiverLearning®, Andrew Muir, 201325
ZFP36L1 controls adiposity and steatosis via post-transcriptional regulation of bile acid metabolism
AASLD LiverLearning®, Thomas Vallim, 201333
Hepatocyte-derived mitochondrial DNA induces fibrogenic activation of stellate cells and promotes fibrosis in non-alcoholic steatohepatitis
AASLD LiverLearning®, Shuangshuang Zhao, 201334
A Negative Feedback Circuit of miR-378, NRF1, AMPK, SIRT1, NF-κB and TNFα Controls the Development of Hepatosteatosis and NASH Progression
AASLD LiverLearning®, Guisheng Song, 201335
Polyprenoic acid, the first-discovered hepatocyte nuclear factor 4 alpha-activating ligand, inhibits liver carcinogenesis.
AASLD LiverLearning®, Taro Yamashita, 201336
Leukotriene B4 Generated by Alveolar Macrophages Drive Hepatocellular Carcinoma Lung Metastasis
AASLD LiverLearning®, Takuto Nosaka, 201337
Obesity-driven hepatocellular carcinoma adapts to lipid-rich conditions by CPT2 down-regulation and promotes carcinogenesis through acylcarnitine accumulation
AASLD LiverLearning®, Naoto Fujiwara, 201338
MicroRNA-206 Prevents the Development of Hepatocellular Carcinoma Via Modulation of cMet and Cdk6 Expression
AASLD LiverLearning®, Guisheng Song, 201339
Epigenetic and paracrine control of hepatic cancer stemness
AASLD LiverLearning®, Manlio Vinciguerra, 201340
Clinicopathological characteristics and mutational profile of PD-L1 positive hepatocellular carcinoma
AASLD LiverLearning®, Naoshi Nishida, 201341
Next-Generation Sequencing Improves the Detection of Malignant Biliary Strictures: A Large Prospective Study of Bile Duct Brushings/Biopsies
AASLD LiverLearning®, Aatur Singhi, 201349
Identification Of Novel Viral Single Nucleotide Variants Associated With Baseline HBV DNA Levels And HBeAg Status In Chronic Hepatitis B Patients.
AASLD LiverLearning®, Ondrej Podlaha, 201350
Cellular Bioenergetics: A Promising Biomarker in Management of Patients with Alcoholic Liver Disease
AASLD LiverLearning®, Ashwani Singal, 201351
Genomic and transcriptomic analysis reveal tumor suppressive effect of TGF-β signaling in liver cancer are associated with impaired DNA damage repair pathways
AASLD LiverLearning®, Lopa Mishra, 201352
Progression of alcoholic liver disease to severe alcoholic hepatitis is characterized by decreased activity of transcription factors implicated in hepatocyte differentiation
AASLD LiverLearning®, Josepmaria Argemi, 201353
The Rising Healthcare Burden of Alcoholic Cirrhosis in the United States
AASLD LiverLearning®, Jessica Mellinger, 201354
Use of an Innovative Telehealth Platform to Reduce Readmissions and Enable Patient-Centered Care in Cirrhotic Patients
AASLD LiverLearning®, Vandana Khungar, 201355
Liver Cirrhosis and Cancer: Comparison of Mortality
AASLD LiverLearning®, Dong Joon Kim, 201356
Significant Declines in the Proportion of Advanced Tumor Stage at Diagnosis Among Adults with Hepatocellular Carcinoma Reflect the Success of Cancer Screening and Surveillance Programs in the U.S.
AASLD LiverLearning®, Jennifer Wang, 201357
The Characteristics and Predictors of Postpartum Hepatitis Flares in Women with Chronic Hepatitis B
AASLD LiverLearning®, Calvin Pan, 201365
Novel Multiparametric Magnetic Resonance Elastography (MRE) Protocol Accurately Predicts Early NASH and Disease Activity
AASLD LiverLearning®, Alina Allen, 201366
BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: A phase 2 study
AASLD LiverLearning®, Arun Sanyal, 201367
Accuracy of vibration controlled transient elastography (VCTE) in grading steatosis and staging fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): a prospective multicenter study
AASLD LiverLearning®, Mohammad Siddiqui, 201368
Performance of liver stiffness by FibroScan in a Large Prospective Multicenter UK Study: Applicability, Reliability, Diagnostic Performance and Influence of The Probe Type And Of Steatosis on the Liver Stiffness Measurement
AASLD LiverLearning®, Philip Newsome, 201369
norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study
AASLD LiverLearning®, Michael Trauner, 201370
4D Dynamic FDG-PET correlates with hepatic inflammation and steatosis in patients with non-alcoholic steatohepatitis
AASLD LiverLearning®, Souvik Sarkar, 201371
Deficiency of bile acid transporter Ostα alters plasma oxysterol mediated Lxrα/β signaling and lipid accumulation in mouse adipose
AASLD LiverLearning®, Supriya Kulkarni, 201372
Anti-inflammatory effects of miR-21 depletion in the macrophage response to cholestatic liver injury
AASLD LiverLearning®, Keisaku Sato, 201373
100% SVR with 8 weeks of ledipasvir/sofosbuvir in HIV-infected Men with Acute HCV Infection: Results from the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals)
AASLD LiverLearning®, Susanna Naggie, 201381
Impact of HCV Treatment before vs. after Renal Transplantation on Time from Listing to Transplantation: A Multi-Center Study
AASLD LiverLearning®, David Chascsa, 201382
Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program
AASLD LiverLearning®, Ashley Brown, 201383
Heritability and shared gene effects of novel gut microbiome associated serum metabolite in NAFLD: A twin and family study
AASLD LiverLearning®, Cyrielle Caussy, 201384
Dynamic adaptations of intestinal microbiota after liver transplantation
AASLD LiverLearning®, Anne-Catrin Uhlemann, 201385
NLRP6 inflammasome-mediated dysbiosis augments acetaminophen induced acute liver injury
AASLD LiverLearning®, Kai Schneider, 201386
Maternal exposure to the bacterial-derived Butyrate protects neonatal mice against experimental biliary atresia
AASLD LiverLearning®, Yu Zhu, 201387
Metagenomic Analysis of Bacteria-Derived Extracellular Vesicles as Biomarkers for Hepatocellular Carcinoma
AASLD LiverLearning®, Eun Ju Cho, 201388
Intestinal Farnesoid X Receptor Deficiency Exacerbates Alcoholic Steatohepatitis
AASLD LiverLearning®, Mingxing Huang, 201389
Frequency, Evaluation and Subsequent Clinical Outcomes of Cirrhosis Patients with Abnormal Imaging Findings during Surveillance for Hepatocellular Carcinoma
AASLD LiverLearning®, Neehar Parikh, 201397
Routine Hepatocellular Carcinoma Surveillance for Hepatitis C Virus-Infected Alaska Native Persons Associated with Increased Likelihood of HCC Diagnosis at an Early Stage During 1991-2016.
AASLD LiverLearning®, Prabhu Gounder, 201398
PyC3A: A Novel Manganese MRI Contrast Agent for the Evaluation of Hepatic Neoplasms
AASLD LiverLearning®, Derek Erstad, 201399
Less Than Half of Hepatocellular Carcinoma Patients Among the 1945-1965 Birth Cohort in the U.S. Were Within Milan Criteria at Time of Diagnosis
AASLD LiverLearning®, Ann Robinson, 201400
Combination of Killer Immunoglobulin-like Receptor and HLA Genes is Associated with Hepatitis C Virus-Related Hepatocellular Carcinoma
AASLD LiverLearning®, Takeji Umemura, 201401
Superiority of Avatrombopag (AVA) to Placebo (PBO) for the Treatment of Chronic Liver Disease (CLD)-Associated Thrombocytopenia (TCP) in Patients Undergoing Scheduled Procedures: Results of 2 Randomized, PBO-Controlled Phase 3 Studies
AASLD LiverLearning®, Norah Terrault, 201402
Impact of SVR in the development of all complications and fibrosis regression in a cohort of patients treated with interferon-base Triple Therapy and Direct Acting Antiviral
AASLD LiverLearning®, Christie Perelló, 201403
OCR-002 (Ornithine Phenylacetate) is a Potent Ammonia Scavenger as Demonstrated in Phase 2b STOP-HE Study
AASLD LiverLearning®, Stanley Bukofzer, 201404
Increased myocardial extracellular volume define patients with more advanced cirrhosis and at higher risk of mortality: Results from a cardiac MRI and Echo study
AASLD LiverLearning®, Signe Wiese, 201405
Long non-coding RNA DANCR correlated to prognosis of Hepatitis C Virus-related hepatocellular carcinoma
AASLD LiverLearning®, Ming-Lung Yu, 201413
Sphingosine-1 Phosphate Receptor 2 plays a critical role in regulating macrophage recruitment and polarization in cholestatic liver injury in Mdr2-/- mice
AASLD LiverLearning®, Lixin Sun, 201414
Differential impact of MT1 and MT2 melatonin receptor deletion on biliary proliferation, senescence, and liver fibrosis during cholestatic liver injury
AASLD LiverLearning®, Nan Wu, 201415
Systems genetics of cholestatic liver disease in ABCB4 deficiency: identification of genetic modifiers that are involved in hepatic cholesterol homeostasis
AASLD LiverLearning®, Marcin Krawczyk, 201416
Vitamin D receptor (VDR) deficiency in Abcb4-/- mice causes an aggravation of primary sclerosing cholangitis features that can be prevented by VDR-independent therapeutic interventions
AASLD LiverLearning®, Ester Gonzalez-Sanchez, 201417
Hepatic X-box Binding Protein 1 (XBP1) Plays a Protective Role in Cholestatic Liver Injury.
AASLD LiverLearning®, Xiaoying Liu, 201418
ER stress-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury
AASLD LiverLearning®, Runping Liu, 201419
Hepatic Stellate Cell-Derived Hyaluronan Synthase 2 Mediates Hyaluronic Acid Production That Promotes Liver Fibrosis
AASLD LiverLearning®, Yoon Mee Yang, 201420
SHP2 promotes liver fibrosis by inducing secretion of hepatic stellate cell-derived PDGFRα-enriched extracellular vesicles
AASLD LiverLearning®, Enis Kostallari, 201421
Early addition of prokinetics reverses gut paralysis and improves survival in critically ill cirrhotics- An open label placebo controlled RCT (Feed Intolerance and Treatment-FIT protocol). NCT02528760
AASLD LiverLearning®, V. Rajan, 201429
Prevalence, spectrum, predictors and outcome of infections in patients with Acute on Chronic Liver Failure
AASLD LiverLearning®, Lovkesh Anand, 201430
Treatment of patients with decompensated cirrhosis with IFN-free regimens is associated with high SVR and early improvement in liver function but increased frequency of decompensation and bacterial infections. Results of prospective cohort.
AASLD LiverLearning®, Gustavo Pereira, 201431
Degree of Hepatic and Systemic Hemodynamic Alterations Predicts Development of AKI and Mortality in Patients With Cirrhosis - A Prospective Cohort Study
AASLD LiverLearning®, RAKHI MAIWALL, 201432
Neutrophil-Gelatinase-Associated Lipocalin and Cystatin C Predict Acute Kidney Injury Progression and Transition to Chronic Kidney Disease in Critically Ill Cirrhotics
AASLD LiverLearning®, RAKHI MAIWALL, 201433
Gene therapy with endothelial-specific liposomal short interfering siRNA targeting kinase insert domain receptor inhibits portosystemic collateralization in portal hypertension
AASLD LiverLearning®, Nuria Pell, 201434
Rho-kinase inhibitor coupled with peptide-modified albumin carrier reduces fibrogenesis and portal pressure in cirrhotic rats without systemic effects
AASLD LiverLearning®, Fernando Magdaleno, 201435
Inflammation provokes endothelial nitric oxide synthase trafficking inducer expression and decreases hepatic nitric oxide biosynthesis and associated endothelial dysfunction in cirrhosis
AASLD LiverLearning®, Balasubramaniyan Vairappan, 201436
The mechanism of splenic fibrosis in portal hypertension: The role of miR133 and connective tissue growth factor (CTGF)
AASLD LiverLearning®, Yasuko Iwakiri, 201437
Establishing Appropriate Goals of Care in Advanced Liver Disease: Individualized Approach
AASLD LiverLearning®, Puneeta Tandon, 202087
Predictors of Mortality in Intensive Care Unit – ICU Scoring Systems
AASLD LiverLearning®, Ayan Sen, 202086
Is Critically Ill Patient a Transplant Candidate?
AASLD LiverLearning®, Julie Heimbach, 202085
President’s Choice Lecture: Lipids, Lipases, Lipoproteins and Liver Disease
AASLD LiverLearning®, Helen Hobbs, 202093
President’s Choice Lecture: Lipids, Lipases, Lipoproteins and Liver Disease
AASLD LiverLearning®, Anna Lok, 202094
Sarcopenia and Support for the Cirrhotic Patient in Intensive Care Unit
AASLD LiverLearning®, Jennifer Lai, 202084
Hepatic Encephalopathy in the ICU
AASLD LiverLearning®, Robert Rahimi, 202083
Acute Liver Failure
AASLD LiverLearning®, Robert Fontana, 202092
Diagnosis and Management of Venous Outflow Disorders
AASLD LiverLearning®, Dominique Valla, 202091
Special Issues Related to Alcoholic Hepatitis Patients in Intensive Care
AASLD LiverLearning®, Hugo Vargas, 202082
Alcohol Use Disorder in the Cirrhotic
AASLD LiverLearning®, Michael Lucey, 202090
Program Chair
AASLD LiverLearning®, Roberto Firpi, 202088
Program Chair
AASLD LiverLearning®, Mindie Nguyen, 202089
Coagulopathy in Liver Disease – Monitoring, Therapies and Indications for Blood Products
AASLD LiverLearning®, R. Todd Stravitz, 202081
Management of Acute Kidney Injury in End-stage Liver Disease Patients
AASLD LiverLearning®, Mitra Nadim, 202080
Sepsis/Septic Shock in Cirrhosis Patients in the ICU
AASLD LiverLearning®, Julia A Wendon, 202079
An Ongoing Extension of a Phase 2 Study of WTX101 in Newly Diagnosed Wilson Disease Patients
AASLD LiverLearning®, Michael Schilsky, 194352
Phase 1, Randomized, Placebo Controlled Study of Givosiran, an Investigational RNA Interference (RNAi) Therapeutic, in Patients with Acute Intermittent Porphyria: Interim study results
AASLD LiverLearning®, Karl Anderson, 194350
Late occult biliary strictures identified in “clinically ideal” pediatric liver transplant (LT) recipients during immunosuppression (IS) withdrawal (iWITH trial)
AASLD LiverLearning®, Emily Perito, 195278
Validating the Mayo model of primary sclerosing cholangitis outcomes in children: data from the Pediatric PSC Consortium
AASLD LiverLearning®, Mark Deneau, 194752
Use of a Comprehensive 66 Gene Panel to Diagnose the Causes of Cholestasis in >700 Individuals
AASLD LiverLearning®, Saul Karpen, 194761
Hedgehog signaling regulates cell differentiation and proliferation in the biliary progenitor cell niche of the extrahepatic bile ducts in vivo, and in the biliary progenitor cell-derived organoids ex vivo
AASLD LiverLearning®, Nataliya Razumilava, 195291
Neurocognitive status in Alagille Syndrome: Results of a Multi-Center Prospective Observational Study
AASLD LiverLearning®, Kathleen Loomes, 194749
Long-term performance of implanted bioprinted human liver tissue in a mouse model of human alpha-1 antitrypsin deficiency
AASLD LiverLearning®, Ben Shepherd, 194355
Treating Obstructive Sleep Apnea and Chronic Intermittent Nocturnal Hypoxia with CPAP Improves Severity of Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Pediatric Patients
AASLD LiverLearning®, Shikha Sundaram, 194777
The ileal bile acid transport inhibitor A4250 reduced pruritus and serum bile acid levels in children with cholestatic liver disease and pruritus: final results from a multiple-dose, open-label, multinational study
AASLD LiverLearning®, Ekkehard Sturm, 194748
Program Chair
AASLD LiverLearning®, Jody Olson, 202076
Program Chair
AASLD LiverLearning®, Ayan Sen, 202077
General Approach
AASLD LiverLearning®, Constantine Karvellas, 202078
Barriers in Treatment of Hepatitis C in Somali Patients: The Epoch of the Direct Acting Antivirals.
AASLD LiverLearning®, Chimaobi Anugwom, 195140
High Cure Rate of Hepatitis C in a Primary Care Clinic for People Who Have Limited Access to Specialty Care
AASLD LiverLearning®, Shobha Joshi, 195128
Real World Treatment Outcomes with Direct Acting Antivirals: Collated Multicentre Data from India
AASLD LiverLearning®, Satyendra Tyagi, 195079
Hepatitis C Direct-Acting Anti-Viral treatment options in patients with epilepsy. A drug-drug interaction dilemma in Hepatitis C infection
AASLD LiverLearning®, Miriam Coghlan, 195129
Smartphone Based Artificial Intelligence Platform Demonstrates High Rates of Adherence and Viral Outcome in Patients Receiving Fixed-Dose Ledipasvir and Sofosbuvir: A Pilot Study
AASLD LiverLearning®, Alain Litwin, 195157
SOF/LDV treatment in patients with transfusion-dependent thalassemia major and HCV genotype 1 or 4 infection: follow-up data on liver stiffness, ferritin and liver iron concentration
AASLD LiverLearning®, Alessandra Mangia, 195104